Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis
| Autor: | Hajime Isomoto, Shigeru Kohno, Saburo Shikuwa, Fuminao Takeshima, Maho Ikeda, Yohei Mizuta, Yoshiyuki Ozono |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty Simvastatin Statin Physiology medicine.drug_class Inflammation Enzyme-Linked Immunosorbent Assay Pharmacology Inflammatory bowel disease Statistics Nonparametric Mice Immune system Internal medicine polycyclic compounds Medicine Animals cardiovascular diseases Colitis biology business.industry Gastroenterology Oxazolone nutritional and metabolic diseases medicine.disease Hydroxymethylglutaryl-CoA reductase TNBS digestive system diseases Endocrinology Trinitrobenzenesulfonic Acid HMG-CoA reductase biology.protein Cytokines lipids (amino acids peptides and proteins) medicine.symptom Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
| Zdroj: | Digestive diseases and sciences. 53(7) |
| ISSN: | 0163-2116 |
| Popis: | PURPOSE: To determine whether simvastatin is able to inhibit inflammation in trinitrobenzene sulfonic acid (TNBS)-induced or oxazalone (OXA)-induced colitis. RESULTS: In the prophylactic protocol, simvastatin dose-dependently suppressed the decrease in body weight and inflammatory grade of TNBS-treated mice. In contrast, in the therapeutic protocol, no significant difference in body weight reduction was observed between simvastatin-treated and control mice. IFN-gamma release from LP cells was significantly suppressed in mice receiving high-dose simvastatin in the prophylactic protocol. In contrast to TNBS colitis, even high-dose prophylactic simvastatin had no suppressive effects on either weight reduction or the inflammatory grade in OXA colitis. CONCLUSION: Our results indicate that simvastatin negatively regulates inflammation in TNBS-induced colitis, but not in OXA-induced colitis. In TNBS-induced colitis, simvastatin suppressed the Th1-polarized immune response. Our findings suggest that simvastatin has potential effects as a therapeutic agent in human inflammatory bowel disease, particularly Crohn's disease. Digestive diseases and sciences, 53(7), pp.1869-1875; 2008 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink